Trump Announces $250 Weight Loss Drugs In Latest ‘TrumpRx’ Deal

President Donald Trump unveiled steep discounts on GLP-1 weight loss drugs in deals with pharmaceutical giants Eli Lilly and Novo Nordisk in a Thursday Oval Office announcement.

The obesity drugs Zepbound, marketed by Lilly, and Wegovy, marketed by Novo Nordisk, will be available at slashed prices through Trump’s innovative direct-to-consumer pharmaceutical marketplace called TrumpRx before the end of the year. Federal health programs will cover the drugs, with copays for Medicare patients as low as $50.

Wegovy, currently priced at $1,350 per month, will cost $250, while Zepbound, currently priced at $1,080 per month, will cost $346. Future GLP-1s taken orally rather than via injection will cost no more than $149 per month under the deal.

Americans spend 520% more for Zepbound than patients in Europe and 1,400% more for Wegovy, Trump said.

The site TrumpRx.com is expected to launch by the end of the year, Center for Medicare and Medicaid Services Commissioner Mehmet Oz said. (RELATED: Trump Unveils Initiative To Claw Back Runaway Drug Prices)

“It’s got to be successful, it’s got my name on it,” Trump said.

In addition, Lilly will invest $27 billion and Novo Nordisk will invest $10 billion to onshore pharmaceutical manufacturing to America.

Trump described the investments as a national security priority.

“We saw during COVID, we made almost no medicines here. We had to go to China,” he said.

The deals stem from an executive order signed in May